Integrative Chiropractic Care and Treatment Insights for OUD

Learn how integrative chiropractic care for OUD can help manage opioid use disorder through advanced techniques and compassionate support.

Abstract

In this educational post, I explain how opioid use disorder (OUD) and musculoskeletal pain reinforce each other, and how integrative chiropractic care can interrupt that loop. I am Dr. Alexander Jimenez, DC, APRN, FNP-BC. At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, I work with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, to combine spinal and soft-tissue care, rehabilitation, functional medicine, and medical oversight.

Chiropractic care does not replace medications for opioid use disorder (MOUD). Buprenorphine and methadone remain the treatments with the strongest mortality benefit. What chiropractic care can do is change the body systems that keep people reaching for opioids: stiff and irritated joints, overloaded muscles, altered movement, heightened pain sensitivity, poor sleep, and an overactive stress response. Large observational studies associate earlier chiropractic care for spine pain with lower odds of receiving a prescription opioid and, in one matched cohort, a lower observed risk of an OUD diagnosis. Those findings are associations, not proof that an adjustment cures addiction. They do support a practical claim I see in clinic: when we restore motion and load tolerance, pain becomes a less dominant driver of use.

This post covers the musculoskeletal physiology, the OUD comorbidities hands-on care can address, my clinical observations, and how this work sits alongside harm reduction and MOUD.

Key Takeaways

• Musculoskeletal pain is both a common on-ramp to prescription opioids and a relapse trigger after OUD is established. Treating the joint, muscle, and movement problem is part of treating the opioid problem.
• Spinal joint dysfunction, myofascial overload, and guarded movement increase nociceptive input. Repeated input can sensitize the dorsal horn and cortex, so ordinary loads feel dangerous.
• High-velocity, low-amplitude adjustments and graded mobilization stimulate joint and muscle mechanoreceptors. The best-supported analgesic pathway is descending inhibition using serotonin and noradrenaline, not a new opioid prescription (Skyba et al., 2003; Bialosky et al., 2009).
• People with noncancer spine pain who receive chiropractic care have lower odds of filling an opioid prescription. A 2025 systematic review estimated 64% lower odds versus usual medical care alone, with a larger association when care started within 30 days, at very low certainty (Emary et al., 2025).
• In a matched cohort of adults with new low back pain, initial spinal manipulative therapy by a chiropractor was associated with a lower two-year risk of an OUD diagnosis than initial ibuprofen (0.24% versus 1.51%; risk ratio 0.20). Residual confounding remains possible (Trager, Cupler, et al., 2025).
• In my El Paso practice, the recurring pattern is thoracolumbar stiffness, hip abductor weakness, and poor diaphragmatic breathing alongside chronic pain and opioid exposure. Restoring those three often lowers pain scores, improves sleep, and makes MOUD easier to stay on (Jimenez, 2026a, 2026b).
• Naloxone, syringe services, and same-day buprenorphine access still come first. No one can rehabilitate a joint if they do not survive the week.

About Our Integrated Care Team

I am a Doctor of Chiropractic (Texas license TX5807; New Mexico NM-DC2182), an Advanced Practice Registered Nurse certified as a Family Nurse Practitioner (FNP-BC), a Certified Functional Medicine Practitioner (CFMP, IFMCP), and a Certified Chiropractic Sports Physician (CCST). My clinical work sits at the intersection of injury, chronic pain, rehabilitation, and addiction-informed primary care. You can find profiles of that work at dralexjimenez.com and on LinkedIn.

Dr. Maria Guadalupe Cardenas, MD, is board-certified in internal medicine and has more than 40 years of experience. She is our Medical Director and Collaborative Physician (NPI 1164426749; Texas MD license J2933). She reviews cardiopulmonary and hepatic risk, medication interactions, infectious disease screening, and MOUD monitoring, including QTc considerations for methadone and liver panels when naltrexone is considered. Chiropractic care in this model is not freestanding addiction treatment. It is musculoskeletal care delivered inside a physician-directed plan.

Our services include medical evaluation, MOUD co-management, integrative chiropractic care, functional movement rehabilitation, functional medicine, personal-injury documentation, nutrition counseling, and linkage to community harm-reduction services.

Why Musculoskeletal Pain Feeds Opioid Use

Most people who develop OUD did not start by seeking euphoria. Many started with a back, neck, shoulder, or joint injury, a prescription that worked for a while, and a nervous system that adapted. National Survey on Drug Use and Health estimates for 2024 found that 4.8 million people aged 12 or older had a past-year opioid use disorder, and only 17% of them (about 818,000 people) received MOUD (Substance Abuse and Mental Health Services Administration [SAMHSA], 2025). Provisional mortality data from the National Center for Health Statistics estimated 69,973 drug overdose deaths in 2025, down from 81,313 in 2024. Opioid-involved deaths fell from an estimated 55,296 to 44,564 (National Center for Health Statistics, 2026). The crisis is smaller than the peak years above 100,000 deaths, and it is still a leading injury-related killer. Synthetic opioids remain the main driver.

The clinical bridge is pain plus a sensitized musculoskeletal system:

• A painful segment or joint keeps firing nociceptors.
• Muscles around that segment guard, fatigue, and develop trigger points.
• The person moves less. Load tolerance drops. The next ordinary task hurts more.
• Opioids briefly dampen that signal, then tolerance, withdrawal, and opioid-induced hyperalgesia make the same tissues feel worse (Lee et al., 2011).
• Use continues “not to get high, but not to feel sick,” and also not to feel the back seize on the way to work.

If we only swap one molecule for another and leave the stiff segment, weak hip, and guarded gait alone, we leave a daily relapse cue in the body.

How Chiropractic Care Affects the Musculoskeletal System

Chiropractic care is a mechanical input with a neurological output. Bialosky and colleagues (2009) described the working model: a force applied to a joint or soft tissue starts a cascade in the peripheral and central nervous systems, and those neurophysiological responses, not a permanent “realignment” in the popular sense, account for most clinical change.

Joint Mechanoreceptors and the Pain Gate

Spinal and peripheral joints are packed with mechanoreceptors. When a segment stops moving well, that afferent traffic changes and nociceptive input becomes relatively louder. A specific adjustment or mobilization restores accessory motion and fires large-diameter A-beta afferents. Those fibers inhibit nociceptive transmission in the dorsal horn, the classic gate-control effect, and they change how the brain maps that region. Patients usually describe this as the joint “letting go” and the pain dropping before strength has had time to change. Strength changes come later, from exercise. The first change is sensory.

Muscle, Fascia, and Trigger Points

Opioid-related pain is rarely only a disc or a facet. Chronic use, poor sleep, low protein intake, and long periods of sitting or guarding produce dense, ischemic muscle. Trigger points in the lumbar erectors, quadratus lumborum, gluteus medius, piriformis, upper trapezius, and suboccipitals refer pain that patients often call “the same pain the pills used to cover.” Soft-tissue work and instrument-assisted mobilization reduce local chemical irritation, improve perfusion, and lower the resting tone that keeps compressing the joint we just mobilized. Without that step, the adjustment is temporary.

Descending Inhibition, Not a New Opioid

Animal work on joint manipulation found that spinal serotonin and alpha-2 adrenergic antagonists blocked the anti-hyperalgesic effect, but opioid and GABA-A antagonists did not (Skyba et al., 2003). That matters clinically. Manual therapy appears to recruit the same descending monoamine pathways the brain uses to turn pain down, rather than flooding mu-opioid receptors the way heroin, fentanyl, or oxycodone do. Reviews of manual therapy reach the same conclusion: analgesic effects are largely neurophysiological and at least partly mediated by descending modulation from the periaqueductal gray and rostral ventromedial medulla (Vigotsky & Bruhns, 2015; Bialosky et al., 2009). This is why chiropractic care can reduce pain in a person on buprenorphine without competing for the receptor that medication is stabilizing.

Movement Patterns and Load Sharing

Pain changes motor control. People with persistent low back pain often stiffen the thoracolumbar junction, underuse the gluteal muscles, and breathe with the neck and chest instead of the diaphragm. That pattern overloads facets, discs, and hip rotators and keeps sympathetic tone high. Our rehabilitation rebuilds the missing pieces in order: diaphragmatic breathing, hip hinge, gluteal endurance, scapular control, then graded loading. Exercise also restores a non-drug source of endogenous opioids and monoamines, improves sleep, and gives patients evidence that their body can be trusted again (Jimenez, 2026b).

Opioid-Induced Hyperalgesia and Central Sensitization

Long-term opioid exposure can increase pain sensitivity through NMDA receptor signaling, glial activation, and disrupted descending inhibition (Lee et al., 2011). Patients then need more drug for the same injury, or they hurt in tissues that never had a structural lesion. Graded manual therapy and movement can retrain that sensitized system. Quantitative sensory testing studies show a systemic rise in pressure-pain threshold after spinal manipulation, although sham-controlled differences are small and the evidence is low quality (Aspinall et al., 2019). I do not promise a reset of central sensitization in one visit. I do expect, over weeks, a wider window of activity that does not flare.

Musculoskeletal Comorbidities of OUD That Chiropractic Care Can Change

OUD is not only a brain disease. The body that carries it is usually deconditioned, injured, inflamed, and sleeping badly. These are the comorbidities I treat directly.

Spine and radicular pain. Low back pain, neck pain, and sciatica are the most common reasons opioids are started. Early chiropractic care for noncancer spine pain is associated with less opioid initiation, particularly if it begins within 30 days (Emary et al., 2025; Whedon et al., 2022). For sciatica, initial chiropractic spinal manipulation has also been associated with fewer opioid-related adverse events, largely because fewer opioid prescriptions were written (Trager, Cupler, Srinivasan, et al., 2025).

Myofascial pain and headache. Guarding, withdrawal-related muscle aching, and jaw or neck tension produce referral patterns that mimic disease. Soft-tissue care and cervical-thoracic mobility work reduce that peripheral drive.

Joint stiffness after inactivity or injury. People who inject drugs, people in early recovery, and people on long-term opioids often present after falls, assaults, motor-vehicle collisions, or months of immobility. Restoring accessory joint motion is the difference between a joint that can be strengthened and a joint that only hurts.

Autonomic and sleep disruption. Sympathetic overactivity in withdrawal and in chronic pain shows up as shallow breathing, elevated resting tone, sweating, and nonrestorative sleep. Slow mobilization, rib and diaphragm work, and resonance-frequency breathing downshift that state. Patients consistently report sleep as the first non-pain gain (Jimenez, 2026a).

Kinesiophobia and deconditioning. Fear of movement predicts disability better than imaging in many spine cases. Graded exposure inside a chiropractic plan reduces that fear. Capacity, not a cleared MRI, is what lets someone return to work without a pill for the drive home.

Postural and occupational overload. In El Paso, this is concrete: warehouse and construction lifting, long border-crossing drives, and desk or data-center work with a forward head. Those loads recreate the original pain generator every shift unless mechanics change.

Wound, infection, and xylazine-related tissue injury are not chiropractic conditions. They need medical and syringe-service care first. We screen for red flags, including progressive neurological deficit, infection, fracture, anticoagulation risk, and severe cardiopulmonary disease, before manual therapy.

Clinical Observations From Practice

These observations are mine, drawn from integrated visits at Injury Medical Clinic PA and described on my clinical site (Jimenez, 2026a, 2026b). They are not a controlled trial.

The pattern I see most often in patients with chronic low back pain and opioid exposure is a stiff thoracolumbar junction, weak hip abductors, and a diaphragm that barely moves. Adjusting the stiff segments, releasing the hip and lumbar myofascia, loading the gluteals, and retraining breathing lowers pain intensity and raises tolerance for daily tasks. When pain falls, cravings tied to that pain usually fall with it.

I have written that my chiropractic goals in OUD-integrated care are to reduce nociceptive input and central sensitization, improve mobility and biomechanics, support autonomic balance through manual therapies that influence reflex arcs, and retrain proprioception, because “patients with chronic pain and OUD often exhibit altered neuromuscular patterns” (Jimenez, 2026a). Chronic substance use adds its own musculoskeletal load: poor posture, low food quality, little training, and repeated trauma, which present as back pain, neck pain, headache, and joint pain (Jimenez, 2026b).

Three recurring presentations shape the plan:

• A person with chronic low back pain who has moved from scarce prescribed oxycodone to heroin and is afraid of withdrawal. Same-day buprenorphine, under Dr. Cardenas’s medical oversight when indicated, comes before any aggressive loading. Gentle mobilization and breathing start in the same week.
• A person stable on methadone with persistent neck pain, poor sleep, and anxiety near the anniversary of the original injury. Cervical and thoracic mobility, scapular endurance, and soft-tissue work address the pain methadone is not designed to fix.
• A younger adult with intermittent oxycodone misuse and alcohol use who wants a non-opioid path. If they are fully detoxified, naltrexone may be considered medically. Chiropractic and rehabilitation become the primary pain strategy.

I wait for stabilization. Once buprenorphine has quieted withdrawal, “the physiological chaos begins to subside. This is the window of opportunity where our other therapies can have a profound impact” (Jimenez, 2026b). Patients with a coordinated manual-therapy and movement plan often report lower pain scores, better sleep, and less stress. That functional progress complements buprenorphine or methadone without adding respiratory-depression risk (Jimenez, 2026a). Frequent visits also create natural points for motivational interviewing and for noticing a relapse early.

I am careful with numbers from the treatment room. Individual patients often improve enough to work and sleep. That does not mean every patient, and it does not mean chiropractic care treated the use disorder. It means the musculoskeletal driver became smaller.

What the Opioid-Reduction Evidence Actually Shows

The association between chiropractic care and less opioid use is consistent and still mostly observational.

• A systematic review and meta-analysis of 2 trials and 18 cohort studies found very low certainty evidence that chiropractic care, added to usual medical care, was associated with 64% lower odds of receiving a prescription opioid for noncancer spine pain (odds ratio 0.36, 95% CI [0.25, 0.52]; absolute risk reduction about 15%). Care within the first 30 days was associated with a larger reduction than care after 30 days. The same review found very low certainty evidence of 73% lower odds of starting long-term opioid therapy (odds ratio 0.27), and moderate certainty evidence of a small improvement in pain and function (Emary et al., 2025).
• An earlier meta-analysis reported the same 64% lower odds of opioid receipt among chiropractic users with spinal pain (Corcoran et al., 2019).
• Among older Medicare beneficiaries with spinal pain, chiropractic care was associated with a 56% lower adjusted risk of filling an opioid prescription within a year (hazard ratio 0.44), again strongest with early care (Whedon et al., 2022).
• Adults with new low back pain who received spinal manipulative therapy from a chiropractor, compared with matched patients started on ibuprofen, had a lower two-year incidence of an OUD diagnosis (0.24% versus 1.51%; risk ratio 0.20), less long-term opioid use (risk ratio 0.23), and fewer opioid prescriptions (risk ratio 0.69). About 49,000 patients remained after matching (Trager, Cupler, et al., 2025). Absolute risks were small in both groups. The design cannot prove that the adjustment itself prevented OUD; patient selection and the clinical relationship may contribute.
• For sciatica, initial chiropractic spinal manipulation was associated with fewer opioid-related adverse events over one year (0.09% versus 0.30%; risk ratio 0.29), along with a lower chance of an opioid prescription (Trager, Cupler, Srinivasan, et al., 2025).

I use these studies to justify early access to chiropractic care for spine and joint pain, especially after injury, so fewer patients ever need a first opioid. I do not use them to tell a person with established severe OUD that manipulation can replace methadone.

Where MOUD and Harm Reduction Still Lead

MOUD is associated with lower mortality, fewer overdoses, less illicit opioid use, and better retention (National Academies of Sciences, Engineering, and Medicine, 2019; Sordo et al., 2017). After a nonfatal overdose, methadone and buprenorphine, not naltrexone in that cohort, were associated with reduced all-cause and opioid-related mortality (Larochelle et al., 2018). Any clinician with a DEA registration can now prescribe buprenorphine for OUD; the X-waiver cap is gone (SAMHSA, 2023).

Buprenorphine is often our first medication because partial agonism creates a ceiling on respiratory depression and office-based starts are feasible. Methadone remains essential for high tolerance and for some pregnancies, through an opioid treatment program. Naltrexone suits a fully detoxified, highly motivated patient and carries a serious overdose risk if it is stopped and opioids are resumed. Micro-induction reduces precipitated withdrawal when fentanyl exposure is likely (Klimas et al., 2021).

Harm reduction is the other nonnegotiable. Naloxone at every visit, fentanyl and xylazine test strips, syringe service linkage, and never-use-alone planning keep people alive long enough for a lumbar spine to matter (Hawk et al., 2017; National Academies of Sciences, Engineering, and Medicine, 2019). Motivational interviewing helps us discuss both medication and the rehab plan without a power struggle (Miller & Rollnick, 2013). Trauma-informed care is the context, given how often adverse childhood experiences and injury anniversaries sit under the pain (SAMHSA, 2014).

A Practical Pathway

First visit. Safety before technique. Naloxone in hand, DSM-5-TR OUD criteria documented, withdrawal assessed with the Clinical Opiate Withdrawal Scale if induction is planned, and red flags screened. Dr. Cardenas’s team handles labs, infectious disease screening, pregnancy testing when relevant, and an electrocardiogram if methadone or other QT-prolonging drugs are in play. I screen movement the same day: which segment is stiff, which muscle is guarding, whether the person can hinge, breathe, and load a hip without fear.

Weeks 1 to 4. Buprenorphine is titrated to suppress withdrawal and craving, often in the 8 to 24 mg range, with micro-induction if fentanyl is likely. Chiropractic care stays graded: mobilize before forceful adjustment if the patient is sensitized, add soft-tissue work to the hip and trunk, and keep motor-control drills short. Sleep and protein intake are the functional medicine priorities, because neither manual therapy nor receptor stabilization works well in a depleted, insomniac body.

After the first month, load progresses. Long-acting injectable buprenorphine is considered if daily dosing is the adherence problem. We recheck workplace mechanics so the job does not undo the plan. Co-prescribed benzodiazepines are tapered only with medical supervision, because that combination raises overdose risk.

Chiropractic care reduces OUD risk to the extent that it reduces the musculoskeletal reasons people start opioids, stay on them, and return to them. The medication keeps the brain stable enough for that work to land. Together, under medical direction, they are a more complete response than either one alone.

References

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).

• Aspinall, S. L., Leboeuf-Yde, C., Etherington, S. J., & Walker, B. F. (2019). Manipulation-induced hypoalgesia in musculoskeletal pain populations: A systematic critical review and meta-analysis. Chiropractic & Manual Therapies, 27, Article 7.

• Bialosky, J. E., Bishop, M. D., Price, D. D., Robinson, M. E., & George, S. Z. (2009). The mechanisms of manual therapy in the treatment of musculoskeletal pain: A comprehensive model. Manual Therapy, 14(5), 531-538.

• Corcoran, K. L., Bastian, L. A., Gunderson, C. G., Steffens, C., Brackett, A., & Lisi, A. J. (2019). Association between chiropractic use and opioid receipt among patients with spinal pain: A systematic review and meta-analysis. Pain Medicine, 21(2), e139-e145.

• Emary, P. C., Corcoran, K. L., Coleman, B. C., Brown, A. L., Ciraco, C., DiDonato, J., Wang, L., Couban, R. J., Sud, A., & Busse, J. W. (2025). Impact of chiropractic care on opioid use for noncancer spine pain: Systematic review and meta-analysis. PAIN Reports, 11(1), e1374.

• Hawk, M., Colter, R. W. S., Egan, J. E., Fisk, S., Reuel Friedman, M., Tula, M., & Kinsky, S. (2017). Harm reduction principles for healthcare settings. Harm Reduction Journal, 14, Article 70.

• Jimenez, A. (n.d.). Dr. Alex Jimenez, DC, APRN, FNP-BC. LinkedIn.

• Jimenez, A. (2026a, August 18). A clinical approach to integrative care solutions for OUD treatment. Injury Medical Clinic PA.

• Jimenez, A. (2026b, August 20). OUD and chronic pain management strategies for integrative care. Injury Medical Clinic PA.

• Klimas, J., Gorfinkel, L., Giacomuzzi, S. M., Rieb, L., Socias, M. E., Fairgrieve, C., & Wood, E. (2021). Buprenorphine microdosing for induction in opioid use disorder: A systematic review. The American Journal on Addictions, 30(4), 305-315.

• Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137-145.

• Lee, M., Silverman, S., Hansen, H., Patel, V., & Manchikanti, L. (2011). A comprehensive review of opioid-induced hyperalgesia. Pain Physician, 14(2), 145-161.

• Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). The Guilford Press.

• National Academies of Sciences, Engineering, and Medicine. (2019). Medications for opioid use disorder save lives. The National Academies Press.

• National Center for Health Statistics. (2026, May 13). U.S. overdose deaths decrease for third consecutive year in 2025. Centers for Disease Control and Prevention.

• Skyba, D. A., Radhakrishnan, R., Rohlwing, J. J., Wright, A., & Sluka, K. A. (2003). Joint manipulation reduces hyperalgesia by activation of monoamine receptors but not opioid or GABA receptors in the spinal cord. Pain, 106(1-2), 159-168.

• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.

• Substance Abuse and Mental Health Services Administration. (2014). SAMHSA’s concept of trauma and guidance for a trauma-informed approach (HHS Publication No. SMA 14-4884).

• Substance Abuse and Mental Health Services Administration. (2023). Removal of DATA-Waiver (X-Waiver) requirement.

• Substance Abuse and Mental Health Services Administration. (2025). 2024 National Survey on Drug Use and Health releases.

• Trager, R. J., Cupler, Z. A., Gliedt, J. A., Fischer, R. A., Srinivasan, R., & Thorfinnson, H. (2025). Association between spinal manipulative therapy for low back pain with or without sciatica and opioid use disorder: A retrospective cohort study. Health Science Reports, 8(9), e71267.

• Trager, R. J., Cupler, Z. A., Srinivasan, R., Harper, E. G., & Perez, J. A. (2025). Association between chiropractic spinal manipulation for sciatica and opioid-related adverse events: A retrospective cohort study. PLOS ONE, 20(1), e0317663.

• Vigotsky, A. D., & Bruhns, R. P. (2015). The role of descending modulation in manual therapy and its analgesic implications: A narrative review. Pain Research and Treatment, 2015, Article 292805.

• Whedon, J. M., Uptmor, S., Toler, A. W. J., Bezdjian, S., MacKenzie, T. A., & Kazal, L. A. (2022). Association between chiropractic care and use of prescription opioids among older Medicare beneficiaries with spinal pain: A retrospective observational study. Chiropractic & Manual Therapies, 30, Article 5.

SEO Tags: opioid use disorder, chiropractic care, musculoskeletal pain, spinal manipulation, opioid-induced hyperalgesia, central sensitization, buprenorphine, methadone, harm reduction, naloxone, low back pain, sciatica, descending pain inhibition, functional rehabilitation, integrative medicine, El Paso, Injury Medical Clinic PA, Dr. Alex Jimenez, Dr. Maria Cardenas, MOUD, fentanyl, trauma-informed care, motor control, myofascial pain, overdose prevention